N-acetyl-cysteine increases the replication of Chlamydia pneumoniae and prolongs the clearance of the pathogen from mice

Dávid Kókai, Tímea Mosolygó, D. Virók, V. Endrész, K. Burián

Research output: Contribution to journalArticle

Abstract

PURPOSE: Within the community, 10% of acquired pneumonia is caused by Chlamydia pneumoniae. N-acetyl-cysteine (NAC) is one of the most commonly used mucolytics in respiratory diseases, but its effect on C. pneumoniae infection has not yet been investigated. In this study, our aim was to investigate whether NAC influences the replication of C. pneumoniae. After determining that NAC does have an effect on C. pneumoniae replication, the effect of an alternative drug called Ambroxol (Ax) was investigated. METHODOLOGY: The in vitro effect of NAC and Ax was studied on C. pneumoniae-infected A549 and McCoy cells. Furthermore, the influence of NAC and Ax was examined in mice infected intranasally with C. pneumoniae. RESULTS: NAC treatment resulted in approximately sixfold more efficient C. pneumoniae growth in tissue culture compared to the untreated control cells, and this effect was shown to be based on the increased binding of the bacterium to the host cells. The C. pneumoniae-infected mice to which NAC was given had prolonged and more severe infections than the control mice. Ax decreased C. pneumoniae replication in vitro, which was partially associated with the increased expression of indolamine 2,3-dioxygenase. In animals, using the adapted usual human dose, Ax did not alter the number of recoverable C. pneumoniae. CONCLUSION: Based on our results, it might be recommended that a mucolytic agent other than NAC, such as Ax, be used in respiratory diseases suspected to be caused by C. pneumoniae.

Original languageEnglish
Article number000716
Pages (from-to)702-708
Number of pages7
JournalJournal of Medical Microbiology
Volume67
Issue number5
DOIs
Publication statusPublished - May 1 2018

Fingerprint

Chlamydophila pneumoniae
Cysteine
Ambroxol
Expectorants
Indoleamine-Pyrrole 2,3,-Dioxygenase
Chlamydia Infections
Infection Control
Pneumonia

Keywords

  • Ambroxol
  • Chlamydia pneumoniae
  • Mouse model
  • N-acetyl-cysteine

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)

Cite this

N-acetyl-cysteine increases the replication of Chlamydia pneumoniae and prolongs the clearance of the pathogen from mice. / Kókai, Dávid; Mosolygó, Tímea; Virók, D.; Endrész, V.; Burián, K.

In: Journal of Medical Microbiology, Vol. 67, No. 5, 000716, 01.05.2018, p. 702-708.

Research output: Contribution to journalArticle

@article{9418dbefc1b64bc38ef607485cc9d76c,
title = "N-acetyl-cysteine increases the replication of Chlamydia pneumoniae and prolongs the clearance of the pathogen from mice",
abstract = "PURPOSE: Within the community, 10{\%} of acquired pneumonia is caused by Chlamydia pneumoniae. N-acetyl-cysteine (NAC) is one of the most commonly used mucolytics in respiratory diseases, but its effect on C. pneumoniae infection has not yet been investigated. In this study, our aim was to investigate whether NAC influences the replication of C. pneumoniae. After determining that NAC does have an effect on C. pneumoniae replication, the effect of an alternative drug called Ambroxol (Ax) was investigated. METHODOLOGY: The in vitro effect of NAC and Ax was studied on C. pneumoniae-infected A549 and McCoy cells. Furthermore, the influence of NAC and Ax was examined in mice infected intranasally with C. pneumoniae. RESULTS: NAC treatment resulted in approximately sixfold more efficient C. pneumoniae growth in tissue culture compared to the untreated control cells, and this effect was shown to be based on the increased binding of the bacterium to the host cells. The C. pneumoniae-infected mice to which NAC was given had prolonged and more severe infections than the control mice. Ax decreased C. pneumoniae replication in vitro, which was partially associated with the increased expression of indolamine 2,3-dioxygenase. In animals, using the adapted usual human dose, Ax did not alter the number of recoverable C. pneumoniae. CONCLUSION: Based on our results, it might be recommended that a mucolytic agent other than NAC, such as Ax, be used in respiratory diseases suspected to be caused by C. pneumoniae.",
keywords = "Ambroxol, Chlamydia pneumoniae, Mouse model, N-acetyl-cysteine",
author = "D{\'a}vid K{\'o}kai and T{\'i}mea Mosolyg{\'o} and D. Vir{\'o}k and V. Endr{\'e}sz and K. Buri{\'a}n",
year = "2018",
month = "5",
day = "1",
doi = "10.1099/jmm.0.000716",
language = "English",
volume = "67",
pages = "702--708",
journal = "Journal of Medical Microbiology",
issn = "0022-2615",
publisher = "Society for General Microbiology",
number = "5",

}

TY - JOUR

T1 - N-acetyl-cysteine increases the replication of Chlamydia pneumoniae and prolongs the clearance of the pathogen from mice

AU - Kókai, Dávid

AU - Mosolygó, Tímea

AU - Virók, D.

AU - Endrész, V.

AU - Burián, K.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - PURPOSE: Within the community, 10% of acquired pneumonia is caused by Chlamydia pneumoniae. N-acetyl-cysteine (NAC) is one of the most commonly used mucolytics in respiratory diseases, but its effect on C. pneumoniae infection has not yet been investigated. In this study, our aim was to investigate whether NAC influences the replication of C. pneumoniae. After determining that NAC does have an effect on C. pneumoniae replication, the effect of an alternative drug called Ambroxol (Ax) was investigated. METHODOLOGY: The in vitro effect of NAC and Ax was studied on C. pneumoniae-infected A549 and McCoy cells. Furthermore, the influence of NAC and Ax was examined in mice infected intranasally with C. pneumoniae. RESULTS: NAC treatment resulted in approximately sixfold more efficient C. pneumoniae growth in tissue culture compared to the untreated control cells, and this effect was shown to be based on the increased binding of the bacterium to the host cells. The C. pneumoniae-infected mice to which NAC was given had prolonged and more severe infections than the control mice. Ax decreased C. pneumoniae replication in vitro, which was partially associated with the increased expression of indolamine 2,3-dioxygenase. In animals, using the adapted usual human dose, Ax did not alter the number of recoverable C. pneumoniae. CONCLUSION: Based on our results, it might be recommended that a mucolytic agent other than NAC, such as Ax, be used in respiratory diseases suspected to be caused by C. pneumoniae.

AB - PURPOSE: Within the community, 10% of acquired pneumonia is caused by Chlamydia pneumoniae. N-acetyl-cysteine (NAC) is one of the most commonly used mucolytics in respiratory diseases, but its effect on C. pneumoniae infection has not yet been investigated. In this study, our aim was to investigate whether NAC influences the replication of C. pneumoniae. After determining that NAC does have an effect on C. pneumoniae replication, the effect of an alternative drug called Ambroxol (Ax) was investigated. METHODOLOGY: The in vitro effect of NAC and Ax was studied on C. pneumoniae-infected A549 and McCoy cells. Furthermore, the influence of NAC and Ax was examined in mice infected intranasally with C. pneumoniae. RESULTS: NAC treatment resulted in approximately sixfold more efficient C. pneumoniae growth in tissue culture compared to the untreated control cells, and this effect was shown to be based on the increased binding of the bacterium to the host cells. The C. pneumoniae-infected mice to which NAC was given had prolonged and more severe infections than the control mice. Ax decreased C. pneumoniae replication in vitro, which was partially associated with the increased expression of indolamine 2,3-dioxygenase. In animals, using the adapted usual human dose, Ax did not alter the number of recoverable C. pneumoniae. CONCLUSION: Based on our results, it might be recommended that a mucolytic agent other than NAC, such as Ax, be used in respiratory diseases suspected to be caused by C. pneumoniae.

KW - Ambroxol

KW - Chlamydia pneumoniae

KW - Mouse model

KW - N-acetyl-cysteine

UR - http://www.scopus.com/inward/record.url?scp=85046460658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046460658&partnerID=8YFLogxK

U2 - 10.1099/jmm.0.000716

DO - 10.1099/jmm.0.000716

M3 - Article

AN - SCOPUS:85046460658

VL - 67

SP - 702

EP - 708

JO - Journal of Medical Microbiology

JF - Journal of Medical Microbiology

SN - 0022-2615

IS - 5

M1 - 000716

ER -